These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37506762)

  • 41. Biotech acquisitions by big pharma: why and what is next.
    Malik NN
    Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aspects of research and development contract terms in the bio/pharmaceutical sector.
    Banerjee T
    Adv Health Econ Health Serv Res; 2012; 23():1-33. PubMed ID: 23156659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lasofoxifene: CP 336156, CP-336156.
    Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands.
    Somers AMJ; Duits AJ; Samson MJ; Schnog JB
    J Cancer Policy; 2024 Jun; 41():100493. PubMed ID: 38876202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The endless frontier? The recent increase of R&D productivity in pharmaceuticals.
    Pammolli F; Righetto L; Abrignani S; Pani L; Pelicci PG; Rabosio E
    J Transl Med; 2020 Apr; 18(1):162. PubMed ID: 32272953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016.
    Gagnon MA; Volesky KD
    Global Health; 2017 Aug; 13(1):62. PubMed ID: 28830481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Situation analysis of R & d activities: an empirical study in Iranian pharmaceutical companies.
    Rasekh HR; Mehralian G; Vatankhah-Mohammadabadi AA
    Iran J Pharm Res; 2012; 11(4):1013-25. PubMed ID: 24250532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biotech companies adapt to big pharma mergers.
    Niiler E
    Nat Biotechnol; 2000 May; 18(5):487-8. PubMed ID: 10802607
    [No Abstract]   [Full Text] [Related]  

  • 53. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [From "Løveapotekets kemiske Fabrik" to LEO Pharma A/S].
    Schrøder P
    Theriaca; 2005; (36):27-118. PubMed ID: 17144611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Commentary: Reconsidering Pharmaceutical Research and Development Investments.
    Gagnon MA
    Healthc Policy; 2023 Feb; 18(3):25-30. PubMed ID: 36917451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):54-63. PubMed ID: 19305768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):e128-53. PubMed ID: 19305760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Target selection and pharma industry productivity: what can we learn from technology S-curve theory?
    Brown D
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):414-8. PubMed ID: 16889225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The year's new drugs & biologics 2014 - Part II: trends & challenges.
    Graul AI; Serebrov M; Cruces E; Tracy M; Dulsat C
    Drugs Today (Barc); 2015 Feb; 51(2):125-52. PubMed ID: 25756068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study.
    Meyers DE; Meyers BS; Chisamore TM; Wright K; Gyawali B; Prasad V; Sullivan R; Booth CM
    Cancer; 2022 Jan; 128(2):311-316. PubMed ID: 34614198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.